ATL1103 Higher Dose Study
- Higher dose clinical study of ATL1103 in acromegaly patients now closed with clinical study report in preparation
- All 3 patients received a therapeutic benefit from the drug with 2 of the 3 patients achieving the goal of sIGF-I normalisation
- sIGF-I levels normalised in 3rd patient who completed an extended (26 weeks) dosing period
- ATL1103 was well tolerated at the doses tested
Ann: ATL1103 Higher Dose Study-ANP.AX, page-4
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
-0.005(4.76%) |
Mkt cap ! $90.15M | |||
| Open | High | Low | Value | Volume |
| 11.0¢ | 11.0¢ | 10.0¢ | $54.97K | 528.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 396468 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 99708 | 1 |
View Market Depth
| Last trade - 16.10pm 01/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |